Matsubara, N., Azad, A., Agarwal, N., Saad, F., Giorgi, U. D., Joung, J. Y., Fong, P. C., Jones, R. J., Zschaebitz, S., Oldenburg, J., Shore, N. D., Dunshee, C. J., Carles, J., Fay, A. P., Cislo, P., Healy, C., Kirker, M., Fizazi, K. (2025). Final patient-reported outcomes (PROs) in unselected men receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as initial treatment for metastatic castration-resistant prostate cancer (mCRPC): Results from the phase 3 TALAPRO-2 study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.11120